NCT03546608View on ClinicalTrials.gov

Tepotinib Hepatic Impairment Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

February 5, 2019

Study Completion Date

February 5, 2019

Conditions
Hepatic Impairment
Interventions
DRUG

Tepotinib

Participants received a single oral dose of tepotinib in Part 1.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33143

Qps Mra, Llc, Miami

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

EMD Serono Research & Development Institute, Inc.

INDUSTRY

NCT03546608 - Tepotinib Hepatic Impairment Trial | Biotech Hunter | Biotech Hunter